eClinicalMed: One Shot a Week Mazdutide, Easy Weight Loss!

Mazdutide (aka IBI362 or LY3305677) is a weekly formulation of a novel glucagon-like peptide-1 (GLP-1) and glucagon receptor bi-agonist that can reduce body weight by up to 6.

The study further explored the safety and efficacy of Mazdutide at doses of 9 mg and 10 mg

This is a randomized, placebo-controlled, multi-dose, multi-dose phase 1b trial of participants aged 18 to 75 years who were overweight (BMI ≥24 kg/m2) with hyperappetite and/or at least one obesity-related complication, or obese (BMI ≥28 kg/m2), each cohort divided into two groups at a 2:1 randomization and received Mazdutide (1 beat/week) or placebo intervention; In the 9 mg cohort, the intervention was 12 weeks (weeks 1-4, 3 mg, weeks 5-8, 6 mg, weeks 9-12, 9 mg); In the 10 mg cohort, the intervention was 16 weeks (weeks 1-4, 2.

From March 1, 2021 to March 26, 2021, a total of 24 participants were recruited, with 8 participants in each cohort assigned to the Mazdutide group and 4 to the placebo group

In the 9 mg cohort, the mean change in body weight from baseline to week 12 was -11.

Overall, Mazdutide was well tolerated at doses as high as 9 mg and 10 mg and showed encouraging safety

Original Source:

Linong Li, et al.